Get the Stockscreener App
25.65
1.72%
-0.45
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $25.65, with a volume of 45.36M.
It is down -1.72% in the last 24 hours and up +3.09% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$26.10
Open:
$25.58
24h Volume:
45.36M
Relative Volume:
0.72
Market Cap:
$145.84B
Revenue:
$62.79B
Net Income/Loss:
$9.84B
P/E Ratio:
14.95
EPS:
1.7156
Net Cash Flow:
$10.38B
1W Performance:
+0.00%
1M Performance:
+3.09%
6M Performance:
+1.14%
1Y Performance:
-2.99%
1-Day Range:
$25.51
$25.68
1-Week Range:
$25.09
$26.31
52-Week Range:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.65 | 148.40B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,064.29 | 973.23B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
220.14 | 526.41B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
219.26 | 385.48B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
147.14 | 278.22B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.26 | 276.52B | 46.69B | 15.29B | 9.25B | 3.4329 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Quilter Plc Cuts Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Sector Gamma AS Increases Stake in Pfizer Inc. $PFE - MarketBeat
UniSuper Management Pty Ltd Increases Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Commerzbank Aktiengesellschaft FI Increases Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Refines Vaccine Toolkit With Matrix M Deal And ViiV Exit - simplywall.st
The Best Stocks to Invest $40 in to Start the New Year Off Right - Finviz
The Best Stocks to Invest $40 in to Start the New Year Off Right - The Motley Fool
Pfizer Inc. $PFE Stock Position Lessened by Resona Asset Management Co. Ltd. - MarketBeat
Rakuten Investment Management Inc. Buys New Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Refocuses Portfolio With Matrix M Deal And ViiV Exit - simplywall.st
Lobbying Update: $2,810,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Pfizer (NYSE:PFE) Stock Price Down 1.7%Here's What Happened - MarketBeat
Asia roundup: Shionogi ups Viiv stake, Fosun spinoff plans, more - BioWorld MedTech
Pfizer CEO Calls RFK's Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research - Benzinga
Pfizer’s New Autoimmune Candidate PF-08065010 Enters Phase 1: What Investors Should Watch - TipRanks
Pfizer Takes Aim at Keytruda in New Phase 3 Lung Cancer Study: What Investors Should Know - TipRanks
Pfizer Advances New COPD Candidate Into Phase 2/3, Adding Depth to Its Post-COVID Pipeline - TipRanks
Pfizer: Expect Another Double Beating For Q1 (Earnings Preview) (NYSE:PFE) - Seeking Alpha
Pfizer Inc. $PFE Shares Purchased by Teacher Retirement System of Texas - MarketBeat
Lockheed Martin Investment Management Co. Grows Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Position Raised by Strs Ohio - MarketBeat
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Will Licensing Novavax’s Matrix-M Adjuvant Reshape Pfizer’s (PFE) Vaccine Platform Strategy? - Yahoo Finance
Pfizer (PFE) Valuation Check As Shares Recover Modestly From Longer Term Weakness - simplywall.st
Pfizer Target of Unusually High Options Trading (NYSE:PFE) - MarketBeat
Pfizer Advances PF-07248144 With New Drug–Interaction Study, Signaling Quiet Pipeline Progress - TipRanks
‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s ‘Anti-Science’ Vaccine Policies - BioSpace
How Is The Market Feeling About Pfizer Inc? - Benzinga
Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap? - Finviz
NVAX Stock Rises Pre-Market As Pfizer Licenses Its Vaccine Technology - Stocktwits
Analysts Favor Novavax Over Moderna After $30M Pfizer Licensing Deal - Intellectia AI
Pfizer CEO Takes Aim at Kennedy Over Vaccines - The Wall Street Journal
Pfizer (NYSE:PFE) Shares Up 1.5%What's Next? - MarketBeat
The Bull Case For Pfizer (PFE) Could Change Following Novavax Matrix-M Adjuvant Licensing DealLearn Why - simplywall.st
Pfizer (PFE) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Novavax Strikes Major Deal with Pfizer, Surge in Stock Likely - StocksToTrade
Pfizer Pockets $1.9B by Offloading Stake in HIV Drugs Company Majority Owned by GSK - MedCity News
(PFE.N) | Stock Price & Latest News - Reuters
Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer - Finviz
Ex-Dividend Reminder: Albertsons Companies, Signet Jewelers and Pfizer - Nasdaq
Here's Why Pfizer Is Willing To Pay $500 Million For Novavax's Matrix-M (NASDAQ:NVAX) - Seeking Alpha
Pfizer CEO on His Relationship With RFK Jr. - Yahoo Finance
Pfizer Inc. (NYSE:PFE) Declares $0.43 Quarterly Dividend - MarketBeat
Pfizer and Novavax ink $530m vaccine delivery licensing deal - Yahoo Finance
3 No-Brainer Dividend Stocks to Buy Right Now -- Including Pfizer - Finviz
Novavax inks license agreement with Pfizer - The Pharma Letter
Novavax signs licensing agreement with Pfizer for vaccine development - Reuters
GSK and Shionogi agree to replace Pfizer's stake in ViiV Healthcare - BioSpectrum Asia
Pfizer Inc. - Britannica
Assessing Novavax (NVAX) Valuation After Pfizer Matrix M Licensing Deal - Yahoo Finance
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.65%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):